INT258526

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 1.11
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (IPMK, BRAF) cytosol (BRAF) nucleolus (IPMK)
plasma membrane (BRAF) kinase activity (IPMK) cytoplasm (BRAF)
Anatomy Link Frequency
thyroid 1
IPMK (Homo sapiens)
BRAF (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 4 27.16 Quite Low
metalloproteinase 4 5.00 Very Low Very Low Very Low
Sicca syndrome 1 5.00 Very Low Very Low Very Low
Glutamate 1 5.00 Very Low Very Low Very Low
Pain 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Thyroid Neoplasm 161 98.60 Very High Very High Very High
Cancer 54 97.48 Very High Very High Very High
Apoptosis 3 95.56 Very High Very High Very High
Carcinoma 23 95.04 Very High Very High Very High
Exanthema 1 67.48 Quite High
Diarrhoea 1 65.56 Quite High
Malignant Neoplastic Disease 4 57.44 Quite High
Multiple Endocrine Neoplasia Type 2b 1 49.32 Quite Low
Metastasis 15 28.48 Quite Low
Small Cell Lung Cancer 2 16.48 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Utilizing an orthotopic anaplastic thyroid carcinoma xenograft model in nude mice, Kim et al have shown that sorafenib, a multikinase inhibitor of RTK, VEGFR, and BRAF kinase, inhibits proliferation of ATC cell lines and inhibits tumor angiogenesis via induction of endothelial apoptosis (Kim et al 2007).
multikinase Negative_regulation (inhibitor) of BRAF in thyroid associated with thyroid neoplasm, cancer and apoptosis
1) Confidence 0.01 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621417 Disease Relevance 1.11 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox